Targets › FCRN
1 program from 1 company in 8 trials: 3 Phase 3, 3 Phase 2, 2 Phase 1; Neurology, Immunology, Other; next expected readout Nov 2026.
Cell surface receptor that transfers passive humoral immunity from the mother to the newborn. Binds to the Fc region of monomeric immunoglobulin gamma and mediates its selective uptake from milk. (UniProt, P55899)
Open in Phaseline: the race on FCRN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| argenx | Empasiprubart FcRn antagonist | FCRN, FCRL5 | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy; Multifocal Motor Neuropathy (MMN); Dermatomyositis; AChR-Ab Seropositive Generalized Myasthenia Gravis … | Nov 2026 |
Chronic Inflammatory Demyelinating Polyneuropathy (2) Multifocal Motor Neuropathy (MMN) (2) AChR-Ab Seropositive Generalized Myasthenia Gravis (2) Dermatomyositis (1) Healthy Volunteers (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.